Rohan Palekar, 89bio CEO
December 7, 2023 07:04 AM ESTUpdated 07:15 AM
Financing
R&D

Up­dat­ed: 89bio prices $150M pub­lic of­fer­ing for PhI­II de­vel­op­ment of NASH drug

Katherine Lewin

News Reporter

89bio an­nounced an up­sized $150 mil­lion pub­lic of­fer­ing of its com­mon stock on Thurs­day, just a few days af­ter the com­pa­ny …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times